Co-Diagnostics, Inc. Received Patent Approval for “Detection Primers for Nucleic Acid Extensions or Amplification Reactions”

Share Article

Co-Diagnostics, Inc. announced that on Friday, September 12, the company received patent approval for Patent No. US 8,815,514 B2, titled “Detection Primers for Nucleic Acid Extensions or Amplification Reactions.”

Co-Diagnostics, Inc. announced that on Friday, September 12, the company received patent approval for Patent No. US 8,815,514 B2, titled “Detection Primers for Nucleic Acid Extensions or Amplification Reactions.”

The patent relates to Co-Diagnostics’ Rapid Detex technology. It applies to primers of a certain configuration and extends to ANY setting in which they are used. This means that the Rapid Detex Primer platform is flexible enough to be applied in the amplification reaction of any nucleic acids, without being limited to those of one specific disease or target gene sequence.

Rapid Detex Primers are engineered to contain a built-in detection mechanism that reduces the need for a separate probe in nucleic acid testing, and they “light up” in the presence of the target nucleic acid.

Co-Diagnostics CEO Dwight Egan noted, “Receiving the protection of the United States Patent Office on our Rapid Detex Primers provides us with further validation of the uniqueness of our approach to molecular diagnostic test design. We are pleased to be able to market tests based on this platform in the months to come.”

About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Dwight Egan
Visit website